M

Mylan To Pay $465M To Settle EpiPen Medicaid Pricing Scandal; Critics Call Deal “Inadequate”

Amid recent revelations that EpiPen maker Mylan has been overcharging U.S. taxpayers for potentially hundreds of millions of dollars since at least 2011, the drug company says it has agreed to pay $465 million to close the book on a federal investigation into its Medicaid pricing — all without admitting any liability. [More]

Phillip Bradshaw

Administrator: Mylan Has Overcharged Medicaid For EpiPen By At Least 10%

Though the EpiPen emergency allergy treatment has been around for decades, the increased demand for the drug and its soaring price tag have caused Medicaid spending on EpiPen to go from around $66 million in 2011 to $365 million in 2015. All this time, claims Andrew Slavitt, Acting Administrator for the Center for Medicare & Medicaid Services, Mylan’s parent company has been shortchanging Medicaid on rebates. [More]

Nearly 25% Of Nursing Homes 'Much Below Average'

Nearly 25% Of Nursing Homes 'Much Below Average'

Of all the unusual gifts you can give Mom or Dad this holiday season, none would be more surprising than a simple card saying, “We’re putting you in a home.” Just make sure you don’t pick a bad one, because nearly a quarter of nursing homes were rated “much below average” in a new monthly federal evaluation.